Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01879748 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
A Phase 1 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01879748 is a Phase 1 study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 64 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01879748, a Phase 1 study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the pharmacokinetics of rasagiline in healthy Japanese and Caucasian subjects after single and multiple doses of rasagiline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rasagiline
Study Locations (1)
California
- Teva Investigational Site 10738 - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01879748
The ClinicalTrials.gov registry entry for NCT01879748 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (90% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01879748 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01879748 about?
NCT01879748 is a clinical study titled "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline". This study is designed to evaluate the pharmacokinetics of rasagiline in healthy Japanese and Caucasian subjects after single and multiple doses of rasagiline.
What is the current status of trial NCT01879748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-06. Estimated completion is 2013-11.
What conditions does trial NCT01879748 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01879748?
The interventions under investigation include: Placebo (DRUG), Rasagiline (DRUG).
Who is sponsoring clinical trial NCT01879748?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01879748 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.